In January 2017, the company announced that it was expanding the pipeline through the acquisition of a majority stake in fellow Israel-based TyrNovo, a privately-held developer of novel small molecules in the immuno-oncology therapeutic field.

That coincided with Kitov's filing of its New Drug Application with the US Food and Drug Administration for its flagship combination drug, KIT-302.